Literature DB >> 22687510

Experimental central nervous system aspergillosis therapy: efficacy, drug levels and localization, immunohistopathology, and toxicity.

Karl V Clemons1, Julie A Schwartz, David A Stevens.   

Abstract

We have shown previously that high-dose lipid amphotericin preparations are not more efficacious than lower doses in aspergillosis. We studied toxicity, drug concentrations and localization, and quantitative infection concurrently, using a 4-day model of central nervous system (CNS) aspergillosis to assess early events. Mice given Aspergillus fumigatus conidia intracerebrally, under a cyclophosphamide immunosuppressive regimen, were treated for 3 days (AmBisome at 3 or 10 mg/kg of body weight, Abelcet at 10 mg/kg, amphotericin B deoxycholate at 1 mg/kg, caspofungin at 5 mg/kg, or voriconazole at 40 mg/kg). Sampling 24 h after the last treatment showed that AmBisome at 3 but not at 10 mg/kg, as well as Abelcet, caspofungin, and voriconazole, reduced brain CFU. All regimens reduced renal infection. Minor renal tubular changes occurred with AmBisome or Abelcet therapy, whereas heart, lung, and brain showed no drug toxicity. Amphotericin B tissue and serum concentrations did not correlate with efficacy. Endothelial cell activation (ICAM-1 and P-selectin in cerebral capillaries) occurred during infection. Amphotericin B derived from AmBisome and Abelcet localized in activated endothelium and from Abelcet in intravascular monocytes. In 10-day studies dosing uninfected mice, minor renal tubular changes occurred after AmBisome or Abelcet at 1, 5, or 10 mg/kg with or without cyclophosphamide treatment; nephrosis occurred only with Abelcet in cyclophosphamide-treated mice. Hepatotoxicity occurred with AmBisome and Abelcet but was reduced in cyclophosphamide-treated mice. Marked CFU reduction by AmBisome at 3 mg/kg occurred in association with relatively more intense inflammation. Abelcet renal localization appears to be a precursor to late nephrotoxicity. Hepatotoxicity may contribute to high-dose Abelcet and AmBisome failures. Our novel observation of endothelial amphotericin localization during infection may contribute to amphotericin mechanism of efficacy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22687510      PMCID: PMC3421548          DOI: 10.1128/AAC.06015-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  41 in total

Review 1.  Worst-rank score analysis with informatively missing observations in clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1999-10

2.  Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis.

Authors:  P David Rogers; Margaret M Pearson; John D Cleary; Donna C Sullivan; Stanley W Chapman
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

3.  Differential expression of selectins by mouse brain capillary endothelial cells in vitro in response to distinct inflammatory stimuli.

Authors:  Caroline Coisne; Christelle Faveeuw; Yannick Delplace; Lucie Dehouck; Florence Miller; Roméo Cecchelli; Bénédicte Dehouck
Journal:  Neurosci Lett       Date:  2005-10-07       Impact factor: 3.046

Review 4.  Immune cell entry to central nervous system--current understanding and prospective therapeutic targets.

Authors:  Catriona T Prendergast; Stephen M Anderton
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2009-12       Impact factor: 2.895

5.  Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.

Authors:  G W Boswell; I Bekersky; D Buell; R Hiles; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B.

Authors:  M Simitsopoulou; E Roilides; J Dotis; M Dalakiouridou; F Dudkova; E Andreadou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model.

Authors:  Jackie Imai; Gaurav Singh; Belkys Fernandez; Karl V Clemons; David A Stevens
Journal:  J Antimicrob Chemother       Date:  2005-05-25       Impact factor: 5.790

8.  Injury of the blood brain barrier and up-regulation of icam-1 in polymicrobial sepsis.

Authors:  Stefan Hofer; Christian Bopp; Christian Hoerner; Konstanze Plaschke; Rita M Faden; Eike Martin; Hubert J Bardenheuer; Markus A Weigand
Journal:  J Surg Res       Date:  2007-08-23       Impact factor: 2.192

9.  Efficacy of oral saperconazole in systemic murine aspergillosis.

Authors:  L H Hanson; K V Clemons; D W Denning; D A Stevens
Journal:  J Med Vet Mycol       Date:  1995 Sep-Oct

10.  Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone.

Authors:  A Louie; A L Baltch; M A Franke; R P Smith; M A Gordon
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

View more
  17 in total

1.  In Vitro and In Vivo Exposure-Effect Relationship of Liposomal Amphotericin B against Aspergillus fumigatus.

Authors:  Maria Siopi; Johan W Mouton; Spyros Pournaras; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

2.  CNS Mold Infections.

Authors:  Jennifer L Lyons
Journal:  Curr Infect Dis Rep       Date:  2013-10-13       Impact factor: 3.725

3.  Reflections on the approach to treatment of a mycologic disaster.

Authors:  David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2013-02-05       Impact factor: 5.191

4.  What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?

Authors:  Dimitrios P Kontoyiannis; David S Perlin; Emmanuel Roilides; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2013-05-06       Impact factor: 9.079

5.  Very-high-dose caspofungin combined with voriconazole to treat central nervous system aspergillosis: substantial penetration of caspofungin into cerebrospinal fluid.

Authors:  François Réminiac; Romain Sonneville; Laurent Massias; Christian Chochillon; Michel Wolff
Journal:  Antimicrob Agents Chemother       Date:  2014-04-14       Impact factor: 5.191

Review 6.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

7.  Chronic Invasive Aspergillus Sinusitis and Otitis with Meningeal Extension Successfully Treated with Voriconazole.

Authors:  Marjolaine Morgand; Blandine Rammaert; Sylvain Poirée; Marie-Elisabeth Bougnoux; Hugo Tran; Romain Kania; Fabrice Chrétien; Gregory Jouvion; Olivier Lortholary
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

8.  In vitro and in vivo evidence for amphotericin B as a P-glycoprotein substrate on the blood-brain barrier.

Authors:  Ji-Qin Wu; Kun Shao; Xuan Wang; Rui-Ying Wang; Ya-Hui Cao; Yun-Qiu Yu; Jin-Ning Lou; Yan-Qiong Chen; Hua-Zhen Zhao; Qiang-Qiang Zhang; Xin-Hua Weng; Chen Jiang; Li-Ping Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

Review 9.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

10.  Efficacy, Biodistribution, and Nephrotoxicity of Experimental Amphotericin B-Deoxycholate Formulations for Pulmonary Aspergillosis.

Authors:  Alicia López-Sánchez; Alba Pérez-Cantero; Carlos Torrado-Salmerón; Adela Martin-Vicente; Víctor García-Herrero; María Ángeles González-Nicolás; Alberto Lázaro; Alberto Tejedor; Santiago Torrado-Santiago; Juan José García-Rodríguez; Javier Capilla; Susana Torrado
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.